Impact of rifaximin use following an initial overt hepatic encephalopathy hospitalization on rehospitalization and costs

References

• Elwir S, Rahimi RS. Hepatic encephalopathy: an update on the pathophysiology and therapeutic options. J Clin Transl Hepatol. 2017;5(2):142–151.
   PubMed Web of Science ®Google Scholar
• Patidar KR, Bajaj JS. Covert and overt hepatic encephalopathy: diagnosis and management. Clin Gastroenterol Hepatol. 2015;13(12):2048–2061. doi: 10.1016/j.cgh.2015.06.039.
   PubMed Web of Science ®Google Scholar
• Neff G, Zachry W. III. Systematic review of the economic burden of overt hepatic encephalopathy and pharmacoeconomic impact of rifaximin. Pharmacoeconomics. 2018;36(7):809–822. doi: 10.1007/s40273-018-0641-6.
   PubMed Web of Science ®Google Scholar
• Stepanova M, Mishra A, Venkatesan C, et al. In-hospital mortality and economic burden associated with hepatic encephalopathy in the United States from 2005 to 2009. Clin Gastroenterol Hepatol. 2012;10(9):1034–1041 e1. doi: 10.1016/j.cgh.2012.05.016.
   PubMed Web of Science ®Google Scholar
• Volk ML, Burne R, Guérin A, et al. Hospitalizations and healthcare costs associated with rifaximin versus lactulose treatment among commercially insured patients with hepatic encephalopathy in the United States. J Med Econ. 2021;24(1):202–211. doi: 10.1080/13696998.2021.1877148.
   PubMed Web of Science ®Google Scholar
• Seraj SM, Campbell EJ, Argyropoulos SK, et al. Hospital readmissions in decompensated cirrhotics: factors pointing toward a prevention strategy. World J Gastroenterol. 2017;23(37):6868–6876. doi: 10.3748/wjg.v23.i37.6868.
   PubMed Web of Science ®Google Scholar
• Sood KT, Wong RJ. Hepatic encephalopathy is a strong predictor of early hospital readmission among cirrhosis patients. J Clin Exp Hepatol. 2019;9(4):484–490. doi: 10.1016/j.jceh.2019.01.005.
   PubMed Web of Science ®Google Scholar
• Tapper EB, Halbert B, Mellinger J. Rates of and reasons for hospital readmissions in patients with cirrhosis: a multistate population-based cohort study. Clin Gastroenterol Hepatol. 2016;14(8):1181–1188.e2. doi: 10.1016/j.cgh.2016.04.009.
   PubMed Web of Science ®Google Scholar
• Bajaj JS, Reddy KR, Tandon P, et al. The 3-month readmission rate remains unacceptably high in a large North American cohort of patients with cirrhosis. Hepatology. 2016;64(1):200–208. doi: 10.1002/hep.28414.
   PubMed Web of Science ®Google Scholar
• Vilstrup H, Amodio P, Bajaj J, et al. Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the American association for the study of liver diseases and the European association for the study of the liver. Hepatology. 2014;60(2):715–735. doi: 10.1002/hep.27210.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. XIFAXAN® (rifaximin) label. 2022.
   Google Scholar
• Bass NM, Mullen KD, Sanyal A, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med. 2010;362(12):1071–1081. doi: 10.1056/NEJMoa0907893.
   PubMed Web of Science ®Google Scholar
• Beauvais B, Whitaker Z, Kim F, et al. Is the hospital Value-Based purchasing program associated with reduced hospital readmissions? J Multidiscip Healthc. 2022;15:1089–1099. doi: 10.2147/JMDH.S358733.
   PubMed Web of Science ®Google Scholar
• Jencks SF, Williams MV, Coleman EA. Rehospitalizations among patients in the medicare fee-for-service program. N Engl J Med. 2009;360(14):1418–1428. doi: 10.1056/NEJMsa0803563.
   PubMed Web of Science ®Google Scholar
• Tapper EB. Building effective quality improvement programs for liver disease: a systematic review of quality improvement initiatives. Clin Gastroenterol Hepatol. 2016;14(9):1256–1265.e3. doi: 10.1016/j.cgh.2016.04.020.
   PubMed Web of Science ®Google Scholar
• McIlvennan CK, Eapen ZJ, Allen LA. Hospital readmissions reduction program. Circulation. 2015;131(20):1796–1803. doi: 10.1161/CIRCULATIONAHA.114.010270.
   PubMed Web of Science ®Google Scholar
• Centers for Medicare & Medicaid Services. Hospital readmissions reduction program (HRRP) 2023 [cited 2023 March 16]. https://www.cms.gov/medicare/medicare-fee-for-service-payment/acuteinpatientpps/readmissions-reduction-program
   Google Scholar
• Centers for Medicare & Medicaid Services. Readmissions measures 2023 [cited 2023 March 13]. https://qualitynet.cms.gov/inpatient/measures/readmission.
   Google Scholar
• Chan L, Chauhan K, Poojary P, et al. National estimates of 30-Day unplanned readmissions of patients on maintenance hemodialysis. Clin J Am Soc Nephrol. 2017;12(10):1652–1662. doi: 10.2215/CJN.02600317.
   PubMed Web of Science ®Google Scholar
• Lin E, Bhattacharya J, Chertow GM. Prior hospitalization burden and the relatedness of 30-Day readmissions in patients receiving hemodialysis. J Am Soc Nephrol. 2019;30(2):323–335. doi: 10.1681/ASN.2018080858.
   PubMed Web of Science ®Google Scholar
• Shaw JA, Stiliannoudakis S, Qaiser R, et al. Thirty-day hospital readmissions: a predictor of higher all-cause mortality for up to two years. Cureus. 2020;12(7):e9308. doi: 10.7759/cureus.9308.
   PubMed Web of Science ®Google Scholar
• Leevy CB, Phillips JA. Hospitalizations during the use of rifaximin versus lactulose for the treatment of hepatic encephalopathy. Dig Dis Sci. 2007;52(3):737–741. doi: 10.1007/s10620-006-9442-4.
   PubMed Web of Science ®Google Scholar
• Neff GW, Kemmer N, Zacharias VC, et al. Analysis of hospitalizations comparing rifaximin versus lactulose in the management of hepatic encephalopathy. Transplant Proc. 2006;38(10):3552–3555. doi: 10.1016/j.transproceed.2006.10.107.
   PubMed Web of Science ®Google Scholar
• Kruger AJ, Aberra F, Black SM, et al. A validated risk model for prediction of early readmission in patients with hepatic encephalopathy. Ann Hepatol. 2019;18(2):310–317. doi: 10.1016/j.aohep.2018.08.001.
   PubMed Web of Science ®Google Scholar
• Volk ML, Tocco RS, Bazick J, et al. Hospital readmissions among patients with decompensated cirrhosis. Am J Gastroenterol. 2012;107(2):247–252. doi: 10.1038/ajg.2011.314.
   PubMed Web of Science ®Google Scholar
• Merative. MarketScan 2023 [cited 2023 March 16]. https://www.merative.com/real-world-evidence.
   Google Scholar
• Kanwal F, Tapper EB, Ho C, et al. Development of quality measures in cirrhosis by the practice metrics committee of the American association for the study of liver diseases. Hepatology. 2019;69(4):1787–1797. doi: 10.1002/hep.30489.
   PubMed Web of Science ®Google Scholar
• Bureau of Labor Statistics. Consumer price index. 2019. https://www.bls.gov/cpi/tables/supplemental-files/home.htm.
   Google Scholar
• Kim DH, Schneeweiss S, Glynn RJ, Lipsitz LA, Rockwood K, Avorn J. Measuring frailty in medicare data: development and validation of a claims-based frailty index. J Gerontol Med Sci. 2017;73(6):980–987.
   Google Scholar
• Courson A, Jones GM, Twilla JD. Treatment of acute hepatic encephalopathy: comparing the effects of adding rifaximin to lactulose on patient outcomes. J Pharm Pract. 2016;29(3):212–217. doi: 10.1177/0897190014566312.
   PubMedGoogle Scholar
• Tapper EB, Aberasturi D, Zhao Z, et al. Outcomes after hepatic encephalopathy in population-based cohorts of patients with cirrhosis. Aliment Pharmacol Ther. 2020;51(12):1397–1405. doi: 10.1111/apt.15749.
   PubMed Web of Science ®Google Scholar
• Stoll AM, Guido M, Pence A, et al. Lack of access to rifaximin upon hospital discharge is frequent and results in increased hospitalizations for hepatic encephalopathy. Ann Pharmacother. 2023;57(2):133–140. doi: 10.1177/10600280221100537.
   PubMed Web of Science ®Google Scholar
• Lum HD, Studenski SA, Degenholtz HB, et al. Early hospital readmission is a predictor of one-year mortality in community-dwelling older medicare beneficiaries. J Gen Intern Med. 2012;27(11):1467–1474. doi: 10.1007/s11606-012-2116-3.
   PubMed Web of Science ®Google Scholar
• Mah JM, Dewit Y, Groome P, et al. Early hospital readmission and survival in patients with cirrhosis: a population-based study. Can Liver J. 2019;2(3):109–120. Summerdoi: 10.3138/canlivj.2018-0025.
   PubMedGoogle Scholar
• Fabrellas N, Moreira R, Carol M, et al. Psychological burden of hepatic encephalopathy on patients and caregivers. Clin Transl Gastroenterol. 2020;11(4):e00159. doi: 10.14309/ctg.0000000000000159.
   PubMedGoogle Scholar
• Galozy A, Nowaczyk S, Sant’Anna A, et al. Pitfalls of medication adherence approximation through EHR and pharmacy records: definitions, data and computation. Int J Med Inform. 2020;136:104092. doi: 10.1016/j.ijmedinf.2020.104092.
   PubMed Web of Science ®Google Scholar